Cancer Network

Nora Janjan, MD, highlights how the inefficiencies in the healthcare system are driving up costs. Meanwhile, the Department of Government Efficiency has the potential to improve outcomes. https://lnkd.in/exTdcut4 #healtheconomics #cancer #oncology

NX-5948 has been granted fast track designation by the FDA for the treatment of adult patients with relapsed or refractory Waldenström macroglobulinemia who have undergone 2 previous lines of therapy including a BTK inhibitor. FDA https://lnkd.in/eNbcJPJP #hematology #cancer #oncology

The FDA has approved encorafenib/cetuximab plus mFOLFOX6 for patients with advanced BRAF V600E+ colorectal cancer. https://lnkd.in/e9EQ25mH #cancer #oncology #crcsm

Cytotoxic T cells play a vital role in the body’s immune defense against tumors. https://lnkd.in/eGtbP5ky #lymsm #cancer #oncology

A panel of experts on multiple myeloma share clinical practices and discuss the transition of care between academic and community oncology settings. https://lnkd.in/evSPWkEV #mmsm #cancer #oncology

CancerNetwork covered the latest data from #SABCS24. Here are the top 10 articles covering potentially practice-changing findings. https://lnkd.in/eqQuZAQY #bcsm #cancer #oncology

Join Cleveland Clinic Taussig Cancer Institute to lead and expand the cutting-edge TCT program, including CAR T-cell and immune therapies. This role offers a unique opportunity to drive world-class care, collaborate with multidisciplinary teams, and advance clinical and research programs. Qualifications: - Board-certified in Hematology/Oncology - Eligible for Ohio medical licensure - Eligible for academic appointment at Case Western Reserve University Apply here: https://ow.ly/g5yb50Uuhxx

Sacituzumab govitecan has been granted the breakthrough therapy designation by the FDA for the treatment of adult patients who have ES-SCLC and have experienced disease progression on or following platinum-based chemotherapy. https://lnkd.in/ec2j2A3D #lcsm #cancer #oncology

Following the 2024 ASCO Annual Meeting, a panel of experts on multiple myeloma review recent updates and discuss evolving treatment practices. https://lnkd.in/eb7ezYv4 #mmsm #cancer #oncology

Hit Rewind with CancerNetwork!  From Around the Practice to Training Algorithms with the Oncology Brothers, CancerNetwork’s video programs brought you expert insights and fresh perspectives on oncology in 2024. Let’s take a trip down memory lane and revisit these valuable resources.    As we rewind through a successful year, we’re gearing up to deliver even more educational content in 2025. But for now, catch up on your favorites under the media tab on our website!    A huge thank-you to the incredible physicians and their institutions who made this content possible: Rafa Fonseca, Mayo Clinic, Samer Al Hadidi, UAMS - University of Arkansas for Medical Sciences, Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute, Hans Lee, MD Anderson Cancer Center, Binod Dhakal, Medical College of Wisconsin, Krina Patel, UT MD ANDERSON CANCER CENTER, Joshua Sabari, NYU Langone Health, Roy Herbst, Yale Cancer Center, Ed Kim, City of Hope, Jyoti Patel, Divya Gupta, Laila Gharzai, Northwestern University, Faith Abodunrin, Creighton University School of Medicine, Robert Cameron, UChicago Medicine, UCSF Health, Noopur Raje, Harvard Medical School and Massachusetts General Hospital, Donna Catamero, Icahn School of Medicine at Mount Sinai, Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO, Cleveland Clinic, Rohit Gosain, MD, Roswell Park Comprehensive Cancer Center, Rahul Gosain, MD, MBA, Wilmot Cancer Institute, Jorge Eduardo Cortes, MD, Augusta University. Your expertise is what makes CancerNetwork a trusted resource for oncology professionals!